Actuate Therapeutics, Inc. Common stock Cash Flow Conversion Efficiency
Actuate Therapeutics, Inc. Common stock cash flow conversion efficiency. Based on the latest financial reports, Actuate Therapeutics, Inc. Common stock (ACTU) has a cash flow conversion efficiency ratio of -0.611x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.68 Million) by net assets ($10.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Actuate Therapeutics, Inc. Common stock (2022–2024)
Cash flow conversion efficiency of Actuate Therapeutics, Inc. Common stock from 2022 to 2024. This chart illustrates how Actuate Therapeutics, Inc. Common stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ACTU share price today for real-time trading data and today's change.
Actuate Therapeutics, Inc. Common stock Cash Flow Conversion Ratio Explained
Actuate Therapeutics, Inc. Common stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Actuate Therapeutics, Inc. Common stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Actuate Therapeutics, Inc. Common stock ranked by their cash flow conversion efficiency. Also see ACTU market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
XIAO-I Corporation American Depositary Shares
NASDAQ:AIXI
|
0.063x |
|
Sun&L Co Ltd
KO:002820
|
-0.006x |
|
Terragen Holdings Ltd
AU:TGH
|
-0.330x |
|
Workspace Group PLC
LSE:WKP
|
0.018x |
|
ALERIO GOLD CORP.
F:3FR0
|
N/A |
|
Norwood Systems Ltd
AU:NOR
|
-0.175x |
|
Jaya Trishindo Tbk PT
JK:HELI
|
0.047x |
|
Eros International Media Limited
NSE:EROSMEDIA
|
-0.061x |
Annual Cash Flow Conversion Efficiency for Actuate Therapeutics, Inc. Common stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Actuate Therapeutics, Inc. Common stock from 2022 to 2024. Review Actuate Therapeutics, Inc. Common stock free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $104.19K | $-21.84 Million | -209.651x | -96685.38% |
| 2023-12-31 | $-99.63 Million | $-21.63 Million | 0.217x | +118.09% |
| 2022-12-31 | $14.83 Million | $-17.79 Million | -1.200x | -- |
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of… Read more